Ibrutix 140 MG (Ibrutinib)

Basic Product Information of Ibrutix 140 MG (Ibrutinib)

How Ibrutix 140 MG (Ibrutinib) Works BTK Pathway Inhibition and Anti-Tumour Mechanism in B-Cell Malignancies

Ibrutinib, the active ingredient in Ibrutix 140 MG, is a first-in-class, first-generation irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK). BTK is a non-receptor tyrosine kinase functioning as a critical intracellular signal transducer downstream of the B-cell receptor (BCR) complex. In normal B-cell biology, BTK activation following antigen binding propagates signals through the PLCγ2–PKCβ–NF-κB signalling axis, regulating B-cell proliferation, differentiation, and survival. In haematological malignancies of B-cell lineage including Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Waldenström’s Macroglobulinemia (WM) chronic BCR signalling and constitutive BTK activation are primary oncogenic drivers sustaining tumour cell survival and enabling tissue homing to lymph nodes and the bone marrow microenvironment.

Ibrutinib works by forming a permanent covalent bond at Cysteine 481 (Cys481) of the BTK active site, producing irreversible enzyme inhibition that persists until new BTK protein is synthesised. This distinguishes Ibrutinib from reversible kinase inhibitors: the duration of BTK suppression substantially exceeds the drug’s plasma half-life (approximately 4–6 hours), ensuring continuous pathway blockade throughout the once-daily dosing interval. By irreversibly blocking BTK, Ibrutix suppresses downstream activation of NF-κB, MAP kinase, AKT/mTOR, and PLCγ2 pathways simultaneously reducing tumour cell proliferation, preventing anti-apoptotic BCL-2 family protein upregulation, and disrupting the chemokine receptor signals (CXCR4 and CXCR5) that anchor malignant B-cells to survival-promoting bone marrow and lymph node stroma. This combined effect on BCR signalling and stromal homing drives malignant B-cells out of protective tissue niches into the peripheral circulation producing a clinically observable, transient lymphocytosis at the start of therapy that does not indicate disease progression.

Ibrutinib additionally inhibits ITK (Interleukin-2-Inducible T-Cell Kinase), a TEC-family kinase expressed in T-cells, which contributes to its efficacy in chronic Graft-versus-Host Disease (cGVHD) by modulating Th2-dominant cytokine polarisation and suppressing pathogenic donor T-cell activity. At therapeutic plasma concentrations, Ibrutinib demonstrates additional inhibitory activity against other TEC-family kinases (TEC, BMX, TXK, RLK) with structural homology to BTK, and carries measurable off-target activity on EGFR and HER2, which may account for adverse effects including diarrhoea and rash. The primary determinant of clinical efficacy in B-cell malignancies remains BTK inhibition. Mediaid Pharmacy’s oncology medicines portfolio includes Ibrutix alongside a comprehensive range of targeted therapies and specialty haematology-oncology medicines for physicians and patients worldwide.

Approved Indications for Ibrutix 140 MG (Ibrutinib)

Ibrutix (Ibrutinib) 140mg is indicated for the following haematological conditions in adult patients:

Key Clinical Benefits of Ibrutix (Ibrutinib) 140 MG

How to Take Ibrutix 140 MG (Ibrutinib) Dosage and Administration Guidelines

Clinical Monitoring Requirements During Ibrutix (Ibrutinib) Treatment

Regular clinical monitoring is essential throughout Ibrutix treatment. Full blood count (FBC) must be checked at baseline and monthly or more frequently during the first months of treatment; Grade ≥3 neutropenia (occurring in approximately 19% of CLL patients) and significant thrombocytopenia require dose interruption or modification per the toxicity management schedule. Cardiac monitoring is critical throughout therapy: Ibrutinib increases the risk of atrial fibrillation (AF) and atrial flutter (overall incidence approximately 6–9% annually; Grade 3 in approximately 3–5%), with risk increasing with treatment duration and background cardiac risk factors. Baseline electrocardiogram (ECG) is recommended for patients with any prior cardiac history, and newly diagnosed AF should be managed with rate or rhythm control agents while carefully evaluating anticoagulation options. Blood pressure must be monitored regularly, as Ibrutinib-associated hypertension occurs in approximately 14% of patients (Grade ≥3 in approximately 8%); antihypertensive therapy should be initiated promptly when indicated. Liver function tests (LFTs) require periodic monitoring throughout treatment. Patients must be assessed for clinical signs of serious infection including Pneumocystis jirovecii pneumonia (PJP), invasive fungal infections, and hepatitis B reactivation (fatal outcomes reported) and for haemorrhagic events (major haemorrhage in approximately 1–6%), second primary malignancies (non-melanoma skin cancer in up to 13% of long-term patients), and tumour lysis syndrome in patients with high tumour burden at treatment initiation.

Drug Interactions and Important Safety Information for Ibrutix (Ibrutinib)

Ibrutinib is metabolised primarily by hepatic CYP3A4 enzymes. Strong CYP3A4 inhibitors including clarithromycin, ketoconazole, itraconazole, voriconazole, posaconazole, and grapefruit juice substantially increase Ibrutinib plasma concentrations and must be avoided; when unavoidable for a short course, reduce Ibrutix to 140mg once daily and resume the full dose after the inhibitor is stopped. Strong CYP3A4 inducers including rifampin (rifampicin), carbamazepine, phenytoin, phenobarbital, and St. John’s Wort substantially reduce Ibrutinib plasma exposure and should be avoided; select alternative agents where clinically possible.

Ibrutinib carries a clinically significant haemorrhagic interaction risk. Warfarin and all vitamin K antagonists are contraindicated with Ibrutinib due to the risk of fatal haemorrhage. Concomitant antiplatelet agents (aspirin, clopidogrel, NSAIDs) or direct oral anticoagulants require formal risk-benefit assessment and close clinical monitoring for bleeding events throughout combined use. Ibrutinib must be withheld at least 3–7 days before and after any elective surgical procedure to minimise operative and post-operative haemorrhagic risk. Patients should inform their treating haematologist or oncologist of all current medications, supplements, and herbal products particularly any agent with anticoagulant, antiplatelet, or CYP3A4-modulating properties before starting Ibrutix.

Side Effects and Precautions of Ibrutix (Ibrutinib)

Who Should Use Ibrutix 140 MG (Ibrutinib)?

Ibrutix is indicated for adult patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in both the first-line and relapsed/refractory settings; for adults with Mantle Cell Lymphoma (MCL) after at least one prior therapy; for adults with Waldenström’s Macroglobulinemia (WM) in any line of therapy; for adults with Marginal Zone Lymphoma (MZL) after failure of one anti-CD20-based therapy; and for adults with chronic Graft-versus-Host Disease (cGVHD) who have failed one or more prior systemic therapy lines. Ibrutix must be prescribed and supervised by a qualified haematologist or oncologist with experience in B-cell malignancy management and targeted kinase inhibitor therapy. A comprehensive pre-treatment assessment including complete blood count, hepatic function tests, cardiac evaluation, hepatitis B virus serology, and formal bleeding risk assessment is mandatory before initiating therapy. Physicians requiring a comprehensive source for oncology specialty medicines including BTK inhibitors, anti-CD20 agents, BCL-2 inhibitors, and other haematology-oncology targeted therapies can consult Mediaid Pharmacy’s oncology portfolio for availability and worldwide supply.

Manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh

Beacon Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh and the leading oncology and specialty medicine company in the country. Beacon was the first company in Bangladesh to export cancer medicines and currently exports to markets across Asia, Africa, Europe, and Latin America. With more than 200 generic drugs and 65 oncology products in its portfolio, Beacon operates under strict WHO-GMP, cGMP, and ISO-certified manufacturing standards. Ibrutix (Ibrutinib) 140mg capsules are one of Beacon’s core haematology-oncology products, providing a high-quality, bioequivalent, and affordable alternative to Imbruvica (AbbVie/Janssen) at a fraction of the originator cost without compromising on the purity, potency, or bioequivalence required for the long-term treatment of B-cell haematological malignancies.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Ibrutix (Ibrutinib)

Mediaid Pharmacy is a trusted global supplier of specialty oncology and targeted haematology-oncology medications. Ibrutix (Ibrutinib) 140mg capsules (120 capsules per bottle) are available through Mediaid Pharmacy with reliable worldwide shipping to South Asia, the Middle East, Africa, Europe, and beyond. Our team provides full order support including pricing confirmation, availability verification, documentation, and delivery tracking for haematologists, oncologists, hospitals, and patients requiring Ibrutix internationally. Contact Mediaid Pharmacy directly via WhatsApp, phone, or WeChat for enquiries about availability and delivery to your country.

Why Choose Ibrutix (Ibrutinib) from Mediaid Pharmacy?

Ibrutix represents a clinically validated and cost-accessible option for the BTK-targeted treatment of B-cell haematological malignancies. As the generic bioequivalent of Imbruvica (AbbVie/Janssen), Ibrutix delivers the same active ingredient Ibrutinib with the same proven irreversible Cys481 BTK inhibition mechanism and the same 140mg capsule formulation, at a dramatically lower price. The availability of the 140mg strength in a 120-capsule bottle supports the full dosing range across all five indications from 140mg for dose-modified regimens up to 420mg (3 capsules) and 560mg (4 capsules) standard once-daily doses within a single product format. Manufactured by Beacon Pharmaceuticals Ltd. under WHO-GMP and cGMP standards, and distributed globally by Mediaid Pharmacy, Ibrutix is the trusted choice for haematologists and patients worldwide seeking proven BTK inhibitor therapy without the financial access barriers associated with originator Imbruvica pricing. For the complete range of oncology medicines available from Mediaid Pharmacy, including anti-CD20 monoclonal antibodies, BCL-2 inhibitors, and other haematological malignancy-targeted treatments, visit our oncology medicines page.

Frequently Asked Questions About Ibrutix 140 MG (Ibrutinib)